BMS-813160 is primarily used in cancer research as a potent and selective dual antagonist of CCR2 and CCR5 chemokine receptors. These receptors play key roles in tumor progression and metastasis by mediating immune cell migration and creating a favorable tumor microenvironment. By blocking CCR2 and CCR5, BMS-813160 helps inhibit the recruitment of immunosuppressive cells such as tumor-associated macrophages and myeloid-derived suppressor cells, thereby enhancing anti-tumor immune responses. It has been investigated in clinical trials, often in combination with other immunotherapies like PD-1 inhibitors, to improve outcomes in solid tumors including pancreatic, colorectal, and non-small cell lung cancers. Its application is focused on modulating the tumor microenvironment to make cancers more responsive to immune attack, representing a promising approach in immuno-oncology.